management of early complications of...
TRANSCRIPT
![Page 1: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/1.jpg)
Management of early complications of chemotherapy
and targeted therapies
Zeki Ustuner MDDepartment of Medical Oncology, Eskişehir Osmangazi University
![Page 2: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/2.jpg)
Emesis and Management
![Page 3: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/3.jpg)
Emesis
• Nausea and vomiting -- devastating side effects of antineoplastic agents
• Uncontrolled emesis affect quality of life and impair compliance with treatment
• About 70- 80% patients experience emesis & 10-44% have anticipatory emesis
![Page 4: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/4.jpg)
Emesis
![Page 5: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/5.jpg)
Categories of Emesis
• Acute - <1 day p chemo
• Delayed - 1-7 days p chemo
• Breakthrough - despite pre-treatment
• Anticipatory - prior to chemo
• Refractory - continued emesis
![Page 6: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/6.jpg)
Emesis
The potential for Chemotherapy induced Nausea and Vomiting (CINV) is influenced by
• Emetogenic potential of antineoplastic agents
• Patient related factors
![Page 7: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/7.jpg)
Emetogenic potential of cytostatics
Chemo-therapy
Risk of emesis w/o antiemesis
Examples
high > 90 % Cisplatin, Dacarbazine, Nitrogen mustard
moderate 30-90% Carboplatin,anthracyclines,ifosfamide, oxaliplatin, irinotecan
low 10-30%Etoposide, gemcitabine, 5- FU, mitoxantrone, capecitabine, docetaxel, paclitaxel,
minimal < 10% Bleomycin, vinblastine, hormones
![Page 8: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/8.jpg)
Patient Related Risk Factors
Navari RM. J Support Oncol 2003;1:89-103
![Page 9: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/9.jpg)
Grading of Nausea and VomitingAdverse Event
Grade 1 (Mild)
Grade 2 (Moderate)
Grade 3(Severe)
Grade 4 (Life
Threatening/ Disabling)
Grade 5
(Death)
Nausea Loss of appetite with no
change in eating habits
Decreased oral intake with no
significantweight loss,
malnutrition, or dehydration; IV fluids indicated
< 24 hrs
Insufficient oral caloric/fluid intake;
IV fluids, tube feedings, or total
parenteralnutrition indicated
24 hrsLife-threateningconsequences
Death
Vomiting 1 episode in 24 hrs
2-5 episodes in 24 hrs; IV fluids
indicated < 24 hrs
6 episodes in 24 hrs; IV fluids or total
parenteralnutrition indicated
24 hrs
![Page 10: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/10.jpg)
mechanism of action
class examplesAntiemetic efficacy
acute emesis
delayed emesis
5-HT3-receptor 5-HT3-antagonists OndansetronGranisetron
++ (+)
multiple Steroids Dexa-methasone
+(+) +(+)
Neurokinin-1-receptor
Neurokinin-1-AntagonistBenzamide
Aprepitant + ++
Dopamin-D2-Receptor
Meto-clopramide
(+) +
GABA-Chlorid-channel
Benzodiazepine Lorazepam,Diazepam
(+) (+)
Dopamin-D2-Receptor
Neuroleptics HaloperidolOlanzapin
(+) (+)
Not known Cannabinoide Dronabinol (+) (+)
Muscarin-Cholin-Rec.
Antihistamine Diphenhy-dramine
- -
![Page 11: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/11.jpg)
Optimal dosage of setrons
Ondansetron 8 mg 16-24 mgGranisetron 1 mg 2 mgTropisetron 5 mg 5 mgDolasetron 100 mg 100-200mgPalonosetron 0.25 mg -
Roila F. Ann Oncol 2006;17(1):20-8 Kris MG. J Clin Oncol 2006;24(18):2932-47
given 30 min. before chemotherapy.
![Page 12: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/12.jpg)
AAcute emescute emesiis follows followiing chemotherapy ng chemotherapy ofof hhiigh rgh riisk emetogensk emetogeniic potentc potentiialal
• The combination of a 5-HT3 antagonist plus a corticosteroid represents the standard of care
• Addition of aprepitant to standard antiemetic therapy improves control
• Palonosetron
![Page 13: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/13.jpg)
AAcute emescute emesiis follows followiing ng chemotherapychemotherapy
• Should be given prophylactic antiemetics• Patients should maintain oral fluid intake• If vomiting persists may require parenteral
antiemetics and/or admission for rehydration.
![Page 14: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/14.jpg)
ANTIEMETICS FOR THE PREVENTION OF ANTIEMETICS FOR THE PREVENTION OF DELAYED EMESIS INDUCED BY HIGH RISK DELAYED EMESIS INDUCED BY HIGH RISK
EMETOGENIC CHEMOTHERAPYEMETOGENIC CHEMOTHERAPY
DELAYED EMESIS FOLLOWINGDELAYED EMESIS FOLLOWINGCISPLATIN CHEMOTHERAPYCISPLATIN CHEMOTHERAPY
• All patients receiving cisplatin at doses ≥ 50 mg/m2 should receive antiemetic prophylaxis for delayed emesis
![Page 15: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/15.jpg)
ANTIEMETICS FOR THE PREVENTION OF ANTIEMETICS FOR THE PREVENTION OF DELAYED EMESIS INDUCED BY HIGH RISK DELAYED EMESIS INDUCED BY HIGH RISK
EMETOGENIC CHEMOTHERAPYEMETOGENIC CHEMOTHERAPY
• Palonosetron• Aprepitant• Cannabinoids Improves Outcomes
![Page 16: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/16.jpg)
Antiemetic guidelines - MASCC, ASCO-
Emetogenic potential
acute emesis(< 24h)
⇒ delayed emesis (> 24h)
High> 90%
5-HT3-RA +dexamethasone +aprepitant
⇒
dexamethasone (day 2-4) +
aprepitant (day 2-3)
Moderate30% - 90%
1. 5-HT3-RA +dexamethasone+aprepitant
2. 5-HT3-RA +dexamethasone
⇒
1. aprepitant (day 2-3)
(+ dexamethasone)
2. dexamethasone or alternative 5-HT3-RA
![Page 17: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/17.jpg)
Antiemetic guidelines - MASCC, ASCO-
Emetogenic potential
acute emesis(< 24h)
⇒ delayed emesis (> 24h)
Low10% - 30%
dexamethasone mono ⇒
No therapy
Minimal< 10%
No therapy⇒
No therapy
Roila F. Ann Oncol 2006;17(1):20-8 Kris MG. J Clin Oncol 2006;24(18):2932-47
![Page 18: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/18.jpg)
The probable most potent antiemetic therapy in PEB
antiemeticsDay
1 2 3 4 5 6 75-HT3-antagonist or
(Palonosetron 0.25 mg i.v.)XX
X X X X
Dexamethasone 8 mg i.v. X X X X X X X
Aprepitant p.o. 125 80 80 80 80 80 80
ASCO 2007
![Page 19: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/19.jpg)
Managing Mucositis
![Page 20: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/20.jpg)
Mucositis
• Stomatitis• Cheliosis• Glossitis• Oral ulceration• Oesophagitis
• Superadded infection (e.g. Candida)• Reduced diatery intake
![Page 21: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/21.jpg)
Mucositis• Mtx• 5 FU• Anthracyclines• Bleomycin• Vinblastin• Actinomycin D• Etoposide• ARA-C
![Page 22: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/22.jpg)
MucositisWorld Health Organization Grading of
Mucositis/Stomatitis
Grade (Symptoms) 0 None I Painless ulcers, erythema, or mild soreness II Painful erythema, edema, or ulcers, but can eat III Painful erythema, edema, or ulcers, but cannot eat IV Requires parental or enteral support V Death
![Page 23: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/23.jpg)
Mucositis Managing
Treatment is supportive and aimed at symptom control
• Maintain oral hygiene (e.g.mouthwash)• Adequate fluid intake• Treat candida• Use analgesia to reduce pain
![Page 24: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/24.jpg)
• Phase 3 trial of palifermin, recombinant human keratinocyte growth factor
• Previous reports from this trial demonstrated that palifermin reduces incidence, severity, and duration of mucositis [1]
• Data reported at ASH examined impact of palifermin on hospital transplantation costs [2]
Impact of Palifermin on Mucositis-Related Transplantation
1. Spielberger R, et al. ASCO 2003. Abstract 3642.2. Elting LS, et al. ASH 2004. Abstract 2191.
Patients with hematologic malignancies
(N = 212)Placebo
(n = 106)
Total-body irradiation and
high-dose chemotherapy
Peripheral blood
progenitor cell transplantation Placebo
(n = 106)
Palifermin60 µg/kg/day
for 3 days(n = 106)
Palifermin60 µg/kg/day
for 3 days(n = 106)
![Page 25: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/25.jpg)
Diarrhea
National Cancer Institute Common Toxicity Criteria for Diarrhoea
Grade 0 : Increase of less than 4 stools/day over baselineGrade 1 :Increase of 4-6 stools/day over baselineGrade 2 :Increase of greater than 7 stools/day over
baseline, incontinenceGrade 3: Life-threatening consequences including
extremely low blood pressure as a result of severe dehydration
Grade 4: Death
![Page 26: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/26.jpg)
FL plus Irinotecan
• Neutropenia, alopecia, fatigue, vomiting and • Diarrhea : any grade was seen in 50 to 88 %
( severe in 9 to 31 %)predisposing factors
older age, low performance status prior pelvic radiationwhitesinherit genetic polymorphisms such as
the UGT1A1*28 allele
![Page 27: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/27.jpg)
Irinotecan-releated diarrhea• Early-onset : (cholinergic excess)
mean duration of symptoms is 30 minutes it is well controlled by atropine.
• Late diarrhea: (6. -11. days) less common with the every three week schedule loperamide treatment
![Page 28: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/28.jpg)
Diarrhea• Other diarrhea-releated drugs: 5 FU, MTX, 6 MP,
ARA-C, Actinomycin D, Anthracyclines
MANAGEMENT• Oral or intravenous hydration• Loperamide, diphenoxylate• Octreotide• Codein phosphate• Dose reduction of MTX or 5 FU may require, if
severe diarrhea
![Page 29: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/29.jpg)
Grading of Constipation
Grade Description
1 Occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema
2 Persistent symptoms with regular use of laxatives or enemas indicated
3 Symptoms interfering with ADL; obstipation with manual evacuation indicated
4 Life-threatening consequences (eg, obstruction, toxic megacolon)
5 Death
![Page 30: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/30.jpg)
Constipation• Vinca-alkoloids (25-33%), thalidomide (35-59%),
opiatesMANAGING• Advise patients on nutritional adjustments, eg,
increasing fiber and fluid intake• Patients should increase their level physical activity,
if possible• Stool softeners (lactulose), mild purgatives (senna)
magnesium salts • Patients should notify physician if no bowel
movement in 3 days
![Page 31: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/31.jpg)
Risk of Chemotherapy-Induced Neutropenia
![Page 32: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/32.jpg)
Incidence of Chemotherapy-Induced Neutropenia in Cancer Patients
• Myelosuppression a major dose-limiting toxic effect of cancer chemotherapy
• Prospective, nationwide study of 2302 cancer patients
– Patients enrolled before beginning chemotherapy
– Mean 3 cycles completed• Neutropenic outcomes
– Neutropenia: ANC nadir < 109/L– Severe neutropenia (SN): ANC
nadir < 0.5 x 109/L– Febrile neutropenia (FN): fever or
infection, ANC nadir < 109/L– Severe FN: fever or infection,
ANC nadir of 0.5 x 109/L
Crawford J, et al. ASH 2004. Abstract 2210.
0%
20%
40%
60%
80%
100%
Pts
expe
rienc
ing
neut
rope
nia
(%)
43%
24%
14%
9%
Severe FNSNNeutropenia FN
90% total
![Page 33: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/33.jpg)
Incidence of Chemotherapy-Induced Neutropenia in Cancer Patients
• First chemotherapy cycle associated with higher rate of neutropenia than 3 subsequent cycles
Crawford J, et al. ASH 2004. Abstract 2210.
10
8
6
4
2
0
All FN events
FN e
vent
s (%
)
Cycle 1
2296
Cycle 2
1975
Cycle 3
1674
Cycle 4
1210n =
First FN event
![Page 34: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/34.jpg)
Febril Neutropenia
• Check full blood count• Look for source of infection• Blood and urine cultures, chest radiograph• Start broad-spectrum antibiotics and G-CSF• Add other drugs for specific clinical indication• Line removal for non-resolving line infections.
![Page 35: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/35.jpg)
Bleeding
• As many as 10% , result from thrombocytopenia,
• abnormalities in plasma levels of the coagulation factors (e.g. L-Asparaginase),
![Page 36: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/36.jpg)
Bleeding • 11% incidence of platelet nadirs < 20,000 µlt
(n:1,192)
• 75 / 718 (10%) patients had an episode of serious hemorrhage (no fatal bleeding occurred at plt > 10,000mlt)
• The risk of hemorrhage was associated with the rapidity of the drop in platelet count and the presence of active infection
![Page 37: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/37.jpg)
Bleeding
• not at significantly increased risk of spontaneous hemorrhage until the platelet count is below 10,000 µlt , if no other risk factors are present
• Patients with active hemorrhage may require transfusion of platelets, (plt 20,000 -50,000 µlt , since platelet dysfunction (e.g. Mithramycine) may be present
![Page 38: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/38.jpg)
Management of Thrombocytopenia
• Platelet transfusions• Dose adjustment
• Avoid medications that may increase risk of bleeding (eg, aspirin)
• Immediately report bruising or uncontrolled bleeding
![Page 39: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/39.jpg)
Thrombocytopenia
![Page 40: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/40.jpg)
Anemia Treatment Options
• Transfusion of 1 U is estimated to increase hemoglobin level by average of 1 g/dL
• Risks: transfusion-related reactions, congestive heart failure, bacterial/viral contamination and infection, and iron overload
![Page 41: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/41.jpg)
Anemia Treatment Options
Erytropoetin • Major benefit is decrease in transfusion
requirements for chemotherapy patients• Risks: higher risk of mortality and tumor
progression, thromboembolism, hypertension and seizures, and pure RBC aplasia
• Indicated only for patients receiving palliative chemotherapy
• Should not be started if hemoglobin > 10 g/dL
![Page 42: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/42.jpg)
Renal Toxicity
• Cisplatin• Carboplatin• MTX• Cyclophosphamide / Ifosphamide• Streptozocin
• Dose modification is needed in renal failure
![Page 43: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/43.jpg)
Hematuria
• Hematuria can be due to therapy-induced hemorrhagic cystitis, commonly from cyclophosphamide and ifosfamide
• Acrolein has cytotoxic effects on the bladder mucosa
• use of the urinary acrolein neutralizer 2-mercaptoethane sulfonate (Mesna)
![Page 44: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/44.jpg)
Tumor Lysis Syndrome
• acute hyperuricemia, urate nephropathy, and acute renal failure,
• hyperkalemia, • hyperphosphatemia • hypocalcemia, • cardiac arrhythmias, and • sudden death
![Page 45: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/45.jpg)
Tumor Lysis Syndrome
• The best management of TLS is prevention • allopurinol, 600 to 900 mg per day orally, should be
initiated 48 hours before therapy • recombinant urate oxidase (uricozyme) • hydration and diuresis of at least 3,000 mL per day, • with urinary pH of at least 7.0 (unclear and
controversial)• mannitol or high-dose furosemide • dialysis
![Page 46: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/46.jpg)
Tumor Lysis Syndrome
Acute life-threatening hyperkalemia • Kayexalate, • intravenous glucose and insulin, • dialysis
Hyperphosphatemia: • aluminum hydroxide antacids, • dialysis
![Page 47: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/47.jpg)
Pulmonary toxicity• can be debilitating and life threatening• Rapid recognition of this problem and its
management are critical if morbidity is to be limited.
• Bleomycin has long been known to cause interstitial pneumonitis (BIP)
• The incidence of BIP is 10%, with a fatality rate of between 1 and 2%
![Page 48: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/48.jpg)
Pulmonary toxicity
• Gemcitabine is associated an uncommon but serious interstitial pneumonitis and which develops rapidly within 72 hours.
• The incidence has been estimated at between 0.02% and 0.06%
• Irinotecan is a topoisomerase 1 inhibitor, which has been linked to pulmonary toxicity.
• Progressive deterioration followed by death was typical, with no response to corticosteroids.
![Page 49: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/49.jpg)
Adult Respiratory Distress Syndrome
ARDS has been reported as a complication of • all-trans retinoic acid therapy in patients
with promyelocytic leukemia (retinoic acid syndrome),
• gemcitabine therapy
• Treatment is primarily supportive
![Page 50: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/50.jpg)
Hepatotoxcity
• Elevated hepatic enzymes: nitrosoureas, ARA-C
• Cholestasis : 6 MP, Azathioprine• Necrosis : Mithramycin• Vena occlusive disease (VOD) : High-dose
alkylating agents (e.g. busulfan, nitrosoureas), 6 MP, 6 TG, ARA-C, azathiaprine
![Page 51: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/51.jpg)
Ocular Toxicity
• Visual disturbance:Blurring: 5 FUTransient cortical blindness: Cisplatin,
carboplatin• Conjunctivitis, dry eyes: 5 FU, Mtx• Exces lacrimation: 5FU, Mtx, Doxorubicin• Cataracts: Busulphan
![Page 52: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/52.jpg)
Hypersensitivity Reaction (HSR) ANAPHYLAXIS
• TYPE I HSR: urticaria, pruritis, angioedema, dyspnoea, bronchospasm and hypotensionL-asp, paclitaxel, etoposide, cisplatin, procarbasine, Rare:anthracyclines, cyclophosphamide, Mtx
• TYPE III HSR : fever, eosinophilia, pneumonitis
![Page 53: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/53.jpg)
Cutaneous Toxicity
![Page 54: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/54.jpg)
Rashes
• Aminoglutethamide• Procarbazine• Chlorambucil• Allopurinol
![Page 55: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/55.jpg)
Photosensitivity
• 5 FU• Vinblastin• DTIC• Thiotepa• Mtx
![Page 56: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/56.jpg)
Chemotherapy Extravasation
EXTRAVASATİON
![Page 57: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/57.jpg)
Irritant drugs
• It may produce pain, phlebitis, or local hypersensitivity reactions
• Irritant = an agent capable of causing pain at the injection site or along the vein without resulting prolonged inflammation or tissue damage
![Page 58: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/58.jpg)
Irritant Drugs• Busulfan• Carmustine (BCNU)• 2-Chlorodeoxyadenosine (2-CdA)• Dacarbazine (DTIC)• Docetaxel• Etoposide (VP-16)• G-CSF and GM-CSF• Mithramycin• Pentostatin• Streptozocin• Teniposide (VM-26)
![Page 59: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/59.jpg)
Vesicant Drugs
• Vesicant = a cancer chemotherapeutic agent capable of forming a blister and/or causing tissue destruction;
• overall incidence, 0.1 - 6.6 %• necrotic ulcers persist for many weeks or
months after the initial extravasation • resulting in loss of function, contractures,
nerve damage, and causalgia
![Page 60: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/60.jpg)
Vesicant Chemotherapeutic Agents • Actinomycin• Daunorubicin• Doxorubicin• Epirubicin• Idarubicin• Mechlorethamine• Mitomycin• Paclitaxel• Vinblastine,Vincristine,Vinorelbine
![Page 61: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/61.jpg)
Management of Chemotherapy Extravasation
• Drug administration is stopped immediately• cross-clamped intravenous line and needle should
then be aspirated and removed• to cool the site with ice packs immediately and to
continue cooling, for 24 hours, • rest and elevation of the limb • Consultation with a plastic surgeon (large-volume
extravasation, or if progressive pain, swelling, or ulceration are evident at 48 hours )
![Page 62: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/62.jpg)
Chemotherapy Extravasation
Treatments for anthracycline extravasations• local injections of corticosteroids, • GM-CSF, sodium bicarbonate, • sodium thiosulfate, or • topical dimethyl sulfoxide (DMSO),• Dexrazoxane• with or without α-tocopherol are all clinically unproven
![Page 63: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/63.jpg)
Chemotherapy Extravasation
• use of corticosteroid injections or cold compresses may exacerbate tissue injurywith
• vinca alkaloids and etoposide .
![Page 64: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/64.jpg)
![Page 65: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/65.jpg)
ALOPESİA
![Page 66: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/66.jpg)
ALOPECİA
FREQUENT and SEVERE• Anthracyclines• Paclitaxel• Ifosfamide• Cyclophosphamide (IV)• Vindesine• Bleomycine• Actinomycin
MODERATE, DOSE DEPENDENT• 5 FU• Mitoxantrone• Etoposide• Methotrexate• Vinblastine• Vincristine• Carmustine• Hydroxyurea
![Page 67: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/67.jpg)
DOCETAXEL
SKİN and NAİL CHANGES
![Page 68: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/68.jpg)
Nail Changes
• Beau’s line: • Pigmentasyon :
anthracyclines, bleomycin, 5 FU, hydroxyurea, alkylating agents
• Oncolyses : 5 FU, doxorubicin, bleomycin
• Brittle nails: 5 FU, Hydroxyurea
![Page 69: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/69.jpg)
Hand and Foot Syndrome• Capecitabine , 5FU, continuous-infusion
doxorubicin, doxorubicin liposomal (18%)high-dose Interleukin-2
• Palmar-plantar erythrodysesthesia • Redness, tenderness, and possibly peeling
of the palms and soles that prevents normal activity.
• Usually mild, has started as early as 2 weeks after start of treatment.
• May require reductions in the dose of the medication.
![Page 70: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/70.jpg)
Hand-Food Syndrome
![Page 71: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/71.jpg)
Hand and Foot Syndrome• Modifying some of your normal daily activities to
reduce friction and heat exposure to your hands and feet
• Avoid long exposure of hands and feet to hot water
• Avoid increased pressure on the soles of the feet or palms of hands
• Dishwashing gloves should not be worn • Cold may provide temporary relief for pain and
tenderness
![Page 72: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/72.jpg)
Radiation Recall
• Actinomycin D• Bleomycin• Doxorubicin• Epirubicin
İntensive steroid therapy
![Page 73: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/73.jpg)
Biologic Therapies
• Hypotension, • Tachyarrhythmias, • Angina, • Myocardial infarction, • Congestive heart failure
have been reported as complications of treatment with interleukin-2 (IL-2), various interferons, and monoclonal antibodies
![Page 74: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/74.jpg)
Thalidomide: Adverse Events• Common adverse events
– Constipation: 55%
– Fatigue: 79%
– Somnolence
– Sensory neuropathy: 54%
– Rash: 30%
• Key grade ≥ 3 toxicities– Deep vein thrombosis: 4-15% (depending on use with steroids)
– Peripheral neuropathy
– Weakness
![Page 75: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/75.jpg)
Lenalidomide: Adverse Events
• Common adverse events– Constipation: 39%– Fatigue: 38%– Diarrhea: 29%– Neutropenia: 28%
• Key grade ≥ 3 toxicities– Deep vein thrombosis: 7%– Neutropenia: 21%– Thrombocytopenia: 10%
![Page 76: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/76.jpg)
adverse events of endocrine therapy (%)
T AM AI • Hot flushes 40.9 35.7• Vaginal bleeding 10.2 5.4• Vaginal discharge 13.2 3.5• Endometrial cancer 0.8 0.2• Venous thromboembolic 4.5 2.8• Joint symptoms 29.4 35.6• Bone Fractures 7.7 11• Hysterectomy 5.1 1.3
![Page 77: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/77.jpg)
Bisphosphonates (BP)
• BP are beneficial in terms of skeletal morbidity and to reduce bone pain including opioid resistant pain
• Zoledronic acid should be considered in all patients with bone metastases from solid tumours
• BP should be considered as soon as bone metastases are diagnosed even if they are asymptomatic
Aapro M., Ann Oncol 19, 2008
![Page 78: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/78.jpg)
Intravenous Bisphosphonates: Adverse Effects
Generally well tolerated but be aware of
• Renal dysfunction• Osteonecrosis of the jaw, and• Acute phase reaction
![Page 79: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/79.jpg)
Bisphosphonates (BP)• Flu-like symptoms: ~ 20%
– Arthralgia, myalgia, nausea, low-grade fever, bone pain– Typically self-limiting
• Hypocalcemia: reported cases– All patients should receive calcium and vitamin D supplementation
• Acute renal toxicity: rare (Zoledronic Acid)– Monitor serum creatinine– Drug not indicated in patients with creatinine clearance < 30 mL/min
• Osteonecrosis of the jaw: 0.6% to 20.0% (Zoledronic Acid)- Remove and treat all dental infections prior to treatment– Maintain good oral hygiene and routine dental care– Avoid elective dental procedures and oral surgeries
Eastham JA. J Urol. 2007;177:17-24.
![Page 80: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/80.jpg)
Management of early complications of targeted therapies
![Page 81: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/81.jpg)
EGFR TKI
• Gefitinib : Rash or acne, diarrhea, elevated liver enzymes
• Erlotinib: Rash, diarrhea
N Engl J Med. 2009;361:247-257
![Page 82: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/82.jpg)
CETUXİMAB-İRİNOTECAN
Advers EventsRashDiarrheaFebrile neutropeniaİnfusion-releated reactions
![Page 83: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/83.jpg)
Trastuzumab
• Infusion-associated symptoms, including fever and chills, primarily with first dose
• Increased incidence of cardiac dysfunction, particularly when administered with anthracycline-based therapy
• Serious adverse events infrequent
Slamon DJ, et al. N Engl J Med. 2001;344:783-792.
![Page 84: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/84.jpg)
FL plus Irinotecan-Bevacizumab• Neutropenia 29• Venous thromboembolic events 18 + 1 ex• Diarrhea 12• Fatigue 10• Vomiting 7• Deep vein thrombosis 7• Pulmonary embolism 7 + 1 ex• Nausea 6• Febrile neutropenia 6 + 1 ex• Hypertension 5• Bleeding 4 (53%, mostly epistaxis)• Arterial thromboembolic events 4 + 1 ex• Proteinuria 2• Gastrointestinal perforation 2 + 1 ex• Wound-healing complications <1• Congestive heart failure 1• Fistula/abscess 1 + 1 ex
Sobrero A,Oncology 2009;77:113–119
![Page 85: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/85.jpg)
İmatinib• Fluid retention, superficial edema, facial edema,
periorbital edema, weight gain• Neutropenia (myelosupression 10% to 30% in CML) • Tumor lysis syndrome (rare)• nausea, vomiting, diarrhea, • skin rashes• myalgia, muscle cramps, fatigue, headache, • Serious but uncommon side effects: (1% to 2%)
hepatic, renal or cardiopulmonary dysfunction
• Management with dose reductions or treatment interruptions.
![Page 86: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/86.jpg)
sunitinib
![Page 87: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/87.jpg)
Sunitinib Advers Events Grade 3-4, %
• Diarrhoea 5• Fatique 8• Stomatitis 3• Vomiting 3• Anorexia 2• Hand-foot Syndrome 6• Hypertension 5• Thrombocytopenia 6• Anemia 4• Neutropenia 6• Yellow skin, rash,skin discolouration,
hypothyroidism, epistaxis, cardiac failure < 1%
(Lancet Oncol 2009; 10: 757–63) (Motzer JR. JCO June 1, 2009)
![Page 88: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/88.jpg)
Sorafenib • Diarrhea (39%)• Hand-foot syndrome (21%)• Anorexia (14%)• Alopecia (14%)
Drug-Related Grade 3/4 Adverse Events Occurring in > 5% of Patients, %
Sorafenib(n = 297)
Placebo (n = 302)
Diarrhea 8 2
Hand-foot syndrome 8 < 1
Hypophosphatemia (11 %), Hypertension (2 %), Abdominal pain (2 %), Thrombocytopenia (4 %),
Llovet JM.N Engl J Med 2008;359:378-90.
![Page 89: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/89.jpg)
LAPATİNİB
• Rash• Diarrhea• Anorexia• Anemia• Asthenia
![Page 90: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/90.jpg)
Bortezomib: Common Adverse EventsAdverse Events, n (%)(N = 331)
All Grades Grade 3/4
Nausea 190 (57) 8 (2)Vomiting 117 (35) 11 (3)Diarrhea 190 (57) 24 (7)Constipation 140 (42) 7 (2)Fatigue 140 (42) 18 (5)Thrombocytopenia 115 (35) 97 (20)Neutropenia 62 (19) 48 (15)Anemia 87 (26) 33 (10)Peripheral neuropathy 120 (36) 26 (8)
Richardson PG, et al. N Engl J Med. 2005;352:2487-2498
![Page 91: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/91.jpg)
Rituximab• Mild-to-moderate infusion-related reactions (eg, chills, fever,
malaise) • usually with the first infusion; fatalities have been reported within
24 hours of infusion;
• Generally self limited, improve with slowing of the infussion, monitor closely and discontinue with grades 3 or 4 infusion reactions
• Persistent hypogammaglobulinemia, B cell depletion• serious viral infection after rituximab treatment (HBV, HCV,
CMV, VZV)• Progressive multifocal leukoencephalopathy • Renal toxicity, Tumor lysis syndrome
• Use with caution in patients with pre-existing cardiovascular disease or prior cardiopulmonary events.(arrhytmias and angina pectoris)
![Page 92: Management of early complications of chemotherapykanser.org/saglik/upload/21_05_13/kurs/Management_of_Early... · •Nausea and vomiting --devastating side effects of antineoplastic](https://reader031.vdocument.in/reader031/viewer/2022011802/5b2b6a1c7f8b9a214a8b5854/html5/thumbnails/92.jpg)
Thank you for your attention
Zeki Üstüner M.D.